Heron Therapeutics (HRTX) director awarded 53,960 RSUs

Rhea-AI Filing Summary

Heron Therapeutics director Sharmila Dissanaike received a grant of 53,960 restricted stock units of common stock. The units were awarded at a price of $0 per share, so she did not pay cash for this equity grant.

The award vests in full on January 30, 2027. Each restricted stock unit represents the right to receive one share of Heron Therapeutics common stock when it vests, giving her 53,960 shares beneficially owned directly after the grant.

Insider Trade Summary

Net Buyer: 53,960 shares

Net Buy 1 txn

Insider Dissanaike Sharmila

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	53,960	$0.00	$0.00

Holdings After Transaction: Common Stock — 53,960 shares (Direct)

Footnotes (1)

1. F1. The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock.

FAQ

What insider transaction did HRTX report for director Sharmila Dissanaike?

Heron Therapeutics reported that director Sharmila Dissanaike received 53,960 restricted stock units of common stock. The equity was granted as an award at $0 per share, increasing her directly owned beneficial holdings to 53,960 shares after the transaction.

How many Heron Therapeutics (HRTX) shares were granted in this Form 4 filing?

The filing shows a grant of 53,960 restricted stock units of Heron Therapeutics common stock. Each unit represents a contingent right to receive one share, so the award corresponds to 53,960 shares beneficially owned directly after the grant.

When do the restricted stock units granted to the HRTX director vest?

The restricted stock units granted to director Sharmila Dissanaike vest in full on January 30, 2027. Once vested, each unit converts into one share of Heron Therapeutics common stock, delivering the full 53,960 shares at that vesting date.

Was there a cash purchase price for the 53,960 HRTX shares reported?

No cash purchase occurred; the 53,960 shares were granted at a price of $0 per share. This indicates a compensatory equity award, not an open-market purchase, with the value realized when the restricted stock units vest into common shares.

What is the nature of ownership for the shares in this Heron Therapeutics Form 4?

The Form 4 indicates that the 53,960 shares underlying the restricted stock units are held as direct ownership. This means director Sharmila Dissanaike is the direct beneficial owner of the award, rather than holding it through an intermediary entity.

What type of security was involved in the Heron Therapeutics (HRTX) insider grant?

The transaction involved Heron Therapeutics common stock delivered through restricted stock units. Each restricted stock unit is a contingent right that, upon vesting, converts into one share of common stock, aligning director compensation with the company’s equity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/03/2026 - 10:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dissanaike Sharmila

(Last) (First) (Middle)

100 REGENCY FOREST DRIVE

SUITE 300

(Street)

CARY NC 27518

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HERON THERAPEUTICS, INC. /DE/ [ HRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		A		53,960(1)	A	$0	53,960	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock.

	/s/Kathryn Lester Attorney-in-fact for Sharmila Dissanaike	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.